Higher Dosing of Rifamycins Does Not Increase Activity against Mycobacterium tuberculosis in the Hollow-Fiber Infection Model-Reference-Cited by-同舟云学术

Higher Dosing of Rifamycins Does Not Increase Activity against Mycobacterium tuberculosis in the Hollow-Fiber Infection Model

Published:2021-03-18 Issue:4 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Pieterman E. D.¹,van den Berg S.¹,van der Meijden A.¹,Svensson E. M.²³,Bax H. I.¹⁴,de Steenwinkel J. E. M.¹

Affiliation:

1. Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, the Netherlands

2. Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands

3. Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden

4. Department of Internal Medicine, Division of Infectious Diseases, Erasmus University Medical Centre, Rotterdam, the Netherlands

Abstract

Improvements in the translational value of preclinical models can allow more-successful and more-focused research on shortening the duration of tuberculosis treatment. Although the hollow-fiber infection model (HFIM) is considered a valuable addition to the drug development pipeline, its exact role has not been fully determined yet.

Funder

European and Developing Countries Clinical Trials Partnership

Innovative Medicines Initiative

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02255-20

Reference47 articles.

1. Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis

2. Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

3. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis;Rustomjee R;Int J Tuberc Lung Dis,2008

4. Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study

5. Activity of moxifloxacin against mycobacteria

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of spectinamide 1599 efficacy against different mycobacterial phenotypes;Tuberculosis;2023-05

2. High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: Evidence for heteroresistance;PLOS Computational Biology;2023-04-13

3. Tuberculosis: Experimental Models, Innovations, and Challenges;Recent Advances in Pharmaceutical Innovation and Research;2023

4. Improving the Drug Development Pipeline for Mycobacteria: Modelling Antibiotic Exposure in the Hollow Fibre Infection Model;Antibiotics;2021-12-10